Tricarbonyldichlororuthenium(II) dimer, the lipid-soluble carbon monoxide-releasing molecule, attenuates Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-1β in murine macrophages.
Animals
Anti-Inflammatory Agents
/ pharmacology
Heme Oxygenase-1
/ genetics
Interleukin-1beta
/ genetics
Lipopolysaccharides
/ isolation & purification
Macrophages
/ drug effects
Membrane Proteins
/ genetics
Mice
NF-kappa B
/ metabolism
Nitric Oxide
/ metabolism
Nitric Oxide Synthase Type II
/ genetics
Organometallic Compounds
/ pharmacology
Phosphorylation
Prevotella intermedia
/ chemistry
RAW 264.7 Cells
STAT1 Transcription Factor
/ metabolism
STAT3 Transcription Factor
/ metabolism
Signal Transduction
Interleukin-1β
Lipopolysaccharide
Nitric oxide
Periodontal disease
Prevotella intermedia
Tricarbonyldichlororuthenium(II) dimer
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
09
2020
revised:
04
11
2020
accepted:
05
11
2020
pubmed:
24
11
2020
medline:
26
5
2021
entrez:
23
11
2020
Statut:
ppublish
Résumé
Carbon monoxide (CO) is increasingly being appreciated as an important mediator that has pleiotropic biological properties and appears to have a possible therapeutic application for a variety of disorders. Nevertheless, whether this gaseous molecule may be utilized as a therapeutic intervention for periodontal disease is unclear. Here, we examined the potential beneficial effect of CO-releasing molecule-2 (CORM-2), a tricarbonyldichlororuthenium(II) dimer, against the elaboration of proinflammatory mediators by murine macrophages challenged with lipopolysaccharide (LPS) isolated from Prevotella intermedia, a pathogenic bacterium implicated in inflammatory periodontal disease. We found that NO and IL-1β production, iNOS protein expression and mRNA expressions of iNOS and IL-1β were significantly down-regulated when LPS-challenged RAW264.7 cells were exposed to CORM-2. In addition, HO-1 expression was upregulated by CORM-2 in cells activated with P. intermedia LPS, and the inhibitory influence of CORM-2 upon NO production was attenuated by tin protoporphyrin IX, an inhibitor of HO activity. PPAR-γ did not function in the attenuation of NO and IL-1β by CORM-2. JNK and p38 phosphorylation caused by LPS was not altered by CORM-2. CORM-2 reduced NF-κB reporter activity and IκB-α degradation elicited by P. intermedia LPS. Additionally, CORM-2 inhibited LPS-induced phosphorylation of STAT1/3. In conclusion, CORM-2 suppresses NO and IL-1β production caused by P. intermedia LPS. CORM-2 exerts its effect by a mechanism involving anti-inflammatory HO-1 induction and attenuation of NF-κB and STAT1/3 activation, independently of PPAR-γ as well as JNK and p38. CORM-2 may hold promise as host response modulation agent for periodontal disease, though further research is indicated to verify the therapeutic effect.
Identifiants
pubmed: 33223468
pii: S1567-5769(20)33657-2
doi: 10.1016/j.intimp.2020.107190
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
IL1B protein, mouse
0
Interleukin-1beta
0
Lipopolysaccharides
0
Membrane Proteins
0
NF-kappa B
0
Organometallic Compounds
0
STAT1 Transcription Factor
0
STAT3 Transcription Factor
0
Stat1 protein, mouse
0
Stat3 protein, mouse
0
tricarbonyldichlororuthenium (II) dimer
0
Nitric Oxide
31C4KY9ESH
Nitric Oxide Synthase Type II
EC 1.14.13.39
Nos2 protein, mouse
EC 1.14.13.39
Heme Oxygenase-1
EC 1.14.14.18
Hmox1 protein, mouse
EC 1.14.14.18
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107190Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.